Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Biogen’s Lowest Diranersen Dose Wins; Failed Dose Response Forces Phase III Rethink

Biogen has revealed mixed CELIA Phase II trial data for diranersen at AAIC 2026. The lowest 60 mg dose slowed clinical decline more than either 115 mg arm, although CELIA aimed to show greater benefit at higher doses. Consequently, the
  • News
Biogen’s Lowest Diranersen Dose Wins; Failed Dose Response Forces Phase III Rethink

Biogen’s Lowest Dose Wins; BIIB080’s Failed Dose Response Raises Phase 3 Risk

Biogen has reported detailed results from the Phase 2 CELIA trial for diranersen (BIIB080) in early Alzheimer’s disease. The drug reduced tau and slowed cognitive decline across several measures. However, the lowest dose produced the strongest effect, so the study
  • News
Biogen’s Lowest Dose Wins; BIIB080’s Failed Dose Response Raises Phase 3 Risk